In 2025, MMC expanded its impact on patient care by partnering with SHINE Technologies to distribute Ilumira (non-carrier-added Lutetium-177), a cutting-edge cancer-fighting isotope, to healthcare providers across the UAE. This strategic collaboration enhances access to targeted radiotherapies, reinforcing our dedication to advancing cancer treatment in the region.
